Smoking Cessation for African Americans with HIV
This study is looking at ways to help African American people living with HIV quit smoking. It's testing two smartphone apps, ESCAPE and quitSTART, both used with nicotine replacement therapy (NRT), against a control group also receiving NRT. The ESCAPE app is designed specifically for Black adults who smoke and have HIV, focusing on anxiety related to smoking. The quitSTART app helps users understand their smoking habits and build skills to quit. Researchers want to see if these apps help people quit smoking for good, and how they affect anxiety and depression. You might be able to join if you are at least 18, identify as Black/African American, live with HIV, smoke cigarettes, are motivated to quit within 14 days, and have moderate to high anxiety or depression. The study plans to enroll 300 participants, but its current recruitment status is unclear.
- Study design
- This study is a randomized controlled trial, meaning participants will be randomly assigned to one of three groups. It plans to include 300 participants.
- What's involved
- You would complete a self-screener, a baseline appointment, 8 weeks of daily assessments, 8 weekly follow-up assessments, 10 monthly check-in surveys, and two longer follow-up appointments at 28 and 54 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 54 weeks after their baseline appointment to assess smoking abstinence, anxiety, and depression.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Enhancing Smoking Cessation for African American People Everywhere
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Michael S. Businelle, Ph.D. · PRINCIPAL_INVESTIGATOR · University of Oklahoma Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- 7-day Biochemically Verified Point Prevalence Abstinence (PPA)Baseline appointment through the 54-week follow-up, inclusive of follow-up assessments (Weeks 1-6, 28, and 54-week).
PPA will be defined as no cigarette smoking within the past 7 days, and will be biochemically verified via assessment of expired carbon monoxide (\< 6 ppm).
- AnxietyBaseline appointment through the 54-week follow-up, inclusive of follow-up assessments (Weeks 1-6, 28, and 54-week)
Anxiety will be evaluated via Overall Anxiety Severity Index Scale (OASIS).
- DepressionBaseline appointment through the 54-week follow-up, inclusive of follow-up assessments (Weeks 1-6, 28, and 54-week).
Depression will be evaluated via the Overall Depression Severity Index Scale (ODSIS).
- HIV (and general) Quality of LifeBaseline appointment through the 54-week follow-up, inclusive of every assessment containing these survey items (weeks 1-6, 28, and 54-week follow-ups)
HIV (and general) quality of life will be evaluated using the the World Health Organization HIV Quality of Life Brief Scale and the EuroQol 5-Dimension 5-Level (EQ-5D-5L).
- HIV Care Adherence/EngagementBaseline appointment through the 54-week follow-up, inclusive of every assessment containing these survey items (weeks 1-6, 28, and 54-week follow-ups)
HIV-related outcomes will be evaluated using the dichotomous variables (e.g., ART medication non-adherence and missed treatment appointments).